1.

Personalizing care for serious conditions

Medicine is becoming more personal and individualized. Mayo Clinic Laboratories is leading the way by making precision care possible through strategic collaborations and innovative solutions. This year, we formed collaborations with organizations like Lucence to bring advanced cancer diagnostics to more patients. Their LiquidHALLMARK® technology is an ultra-sensitive, next-generation sequencing liquid biopsy that delivers actionable insights for targeted therapies based on genomic results.

And it’s not just oncology. We introduced a test to guide transplant anti-rejection drug prescribing and a targeted genetic test for hereditary pancreatitis, ensuring patients get care tailored to their unique needs.

These solutions, developed at Mayo Clinic, highlight our commitment to solving real challenges in patient care.

2.

Detecting neurodegenerative disease earlier

Early diagnosis can change the trajectory of neurological disorders. That’s why we collaborated with Amprion to make their SAAmplify™–αSYN (CSF) test available nationwide. This groundbreaking test detects α-synuclein pathology years before symptoms of Parkinson’s disease, Lewy body dementia, or multiple system atrophy appear.

Furthermore, Mayo Clinic’s research into neurofilament light chain testing opened new possibilities for diagnosing and managing ALS and MS, underscoring our commitment to advancing neurological care.

3.

Bringing AI from concept to clinical practice

Artificial intelligence (AI) continues to reshape medicine. It is no longer a distant promise but a practical tool in the laboratory. In 2025, Mayo Clinic Laboratories integrated AI into workflows to boost accuracy and consistency while speeding up turnaround times and keeping quality consistent. We embraced a collaborative development model to ensure our solutions address real-world challenges.

This approach combines diverse data streams to deliver predictive insights, enhance quality control, and support precision diagnostics.

4.

Making diagnostics more accessible without compromising quality

Mayo Clinic Laboratories is making testing more convenient without compromising quality. As many companies rush into the self-collection space, Mayo Clinic is taking an approach that prioritizes dependable results. One example from 2025 is developing self-collection testing for sexually transmitted diseases, moving closer to delivering solutions that ensure reliable results and support the right follow-up for patients.

5.

Answering complex questions with advanced genomics

Complex cases call for comprehensive tools. That’s why Mayo Clinic Laboratories launched a whole exome sequencing reflex test that offers a cost-effective way to diagnose complex genetic conditions. When a phenotype-driven gene panel is nondiagnostic or inconclusive, this test allows for reflex to full exome analysis using the original sample and sequencing data. It expands the initially targeted variant assessment to a comprehensive evaluation of the protein-coding regions of about 20,000 genes. Then, Mayo Clinic Laboratories provides a report with clinical guidance instead of just a list of variants to better guide care decisions.